These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31431822)

  • 21. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
    Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
    Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Delay in High-Grade Metastatic Prostate Cancer Progression by Dutasteride : A Case Report].
    Yamada Y; Fujiwara H; Somiya S; Fujikawa S; Kamiyama Y; Tamaki M; Kanaoka T
    Hinyokika Kiyo; 2018 Apr; 64(4):187-192. PubMed ID: 29772622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The risks of prostate cancer detection by transrectal ultrasound guide biopsy in Thai men with abnormal prostatic-specific antigen or abnormal digital rectal examination.
    Leewansangtong S; Tantiwong A; Ratanarapee S; Nualyong C; Soontrapa S
    J Med Assoc Thai; 2000 Dec; 83(12):1519-24. PubMed ID: 11253893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital.
    Osterberg EC; Palmer NRA; Harris CR; Murphy GP; Blaschko SD; Chu C; Allen IE; Cooperberg MR; Carroll PR; Breyer BN
    Urol Oncol; 2017 Nov; 35(11):663.e9-663.e14. PubMed ID: 28826701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate cancer detection at low prostate specific antigen.
    Schröder FH; van der Cruijsen-Koeter I; de Koning HJ; Vis AN; Hoedemaeker RF; Kranse R
    J Urol; 2000 Mar; 163(3):806-12. PubMed ID: 10687982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
    Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
    J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Metastatic prostate cancer complicated with chronic disseminated intravascular coagulopathy causing acute renal failure, mimicking thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: pathomechanism, differential diagnosis and therapy related to a case].
    Deme D; Ragán M; Kalmár K; Kovács L; Varga E; Varga T; Rakonczai E
    Magy Onkol; 2010 Dec; 54(4):351-7. PubMed ID: 21163766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
    Janbaziroudsari H; Mirzaei A; Maleki N
    Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of radical prostatectomy from three centres in the UK: clinical presentation and outcome.
    Feneley MR; Gillatt DA; Hehir M; Kirby RS
    Br J Urol; 1996 Dec; 78(6):911-8; discussion 919-20. PubMed ID: 9014719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Diagnostic algorithm based on a multivariate model to reduce the percentage of negative prostatic biopsies in patients with changed PSA or suspicious rectal palpation].
    Valer Algarabel J; Agüera Fernández L; Adot Zurbano JM; Virseda Chamorro M; Marcos Díez J; Gómez López A; Alpuente Román C
    Actas Urol Esp; 2000; 24(7):549-59. PubMed ID: 11011445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer detection yield in repeated biopsy is independent of the diagnosis of earlier biopsies.
    Grepl M; Student V; Furst T; Furstova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Dec; 153(4):297-302. PubMed ID: 20208971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Responding to the challenges of breast cancer in egypt and other arab countries.
    El Saghir NS
    J Egypt Natl Canc Inst; 2008 Dec; 20(4):309-12. PubMed ID: 20571588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience.
    Ramos CG; Valdevenito R; Vergara I; Anabalon P; Sanchez C; Fulla J
    Urol Oncol; 2013 Nov; 31(8):1522-6. PubMed ID: 22687565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is there a link between BPH and prostate cancer?
    Chang RT; Kirby R; Challacombe BJ
    Practitioner; 2012 Apr; 256(1750):13-6, 2. PubMed ID: 22792684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model.
    Catalona WJ; Partin AW; Finlay JA; Chan DW; Rittenhouse HG; Wolfert RL; Woodrum DL
    Urology; 1999 Aug; 54(2):220-4. PubMed ID: 10443714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer.
    Candas B; Cusan L; Gomez JL; Diamond P; Suburu RE; Lévesque J; Brousseau G; Bélanger A; Labrie F
    Prostate; 2000 Sep; 45(1):19-35. PubMed ID: 10960839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Early diagnosis of prostatic carcinoma by random biopsies in 60 patients clinically negative but with PSA greater than 8.9 ng/ml].
    Bianchi A; Bottanelli A; Baroni G; Rovellini P; Sciaraffia G; Toia G; Marcelli G
    Arch Ital Urol Androl; 1997 Dec; 69(5):313-8. PubMed ID: 9477617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.